tafenoquine succinate · 60 Degrees Pharms · NDA 210607
Arakoda
Earliest generic entry, as listed
2 Dec 2035
Blocked by patent: US 10342791, US 10888558, US 11744828, US 12616689. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10342791 | use U-2582 | 2 Dec 2035 |
| US 10888558 | use U-2582 | 2 Dec 2035 |
| US 11744828 | use U-2582 | 2 Dec 2035 |
| US 12616689 | use U-2582 | 2 Dec 2035 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210607 · 001 · RLD | tablet, oral | EQ 100MG BASE | 2 Dec 2035 |